A phase I trial of recombinant human interleukin-1β(OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation
暂无分享,去创建一个
J. Kurtzberg | M. Crump | M. Ross | J. Rabinowitz | C. Modlin | C. Gilbert | W. Peters | M. Elkordy | D. Coniglio | WP Petros | A. Hussein | P. Rubin | J. Vredenburgh | M. Laughlin | B. Meisenberg | WP Petros | W. Petros
[1] C. Verfaillie,et al. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. , 1994, Blood.
[2] T. MacVittie,et al. Therapeutic evaluation of interleukin-1 for stimulation of hematopoiesis in primates after autologous bone marrow transplantation , 1992, Biotherapy.
[3] C. Dinarello. Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.
[4] L. Platanias,et al. Interleukin-1: biology, pathophysiology, and clinical prospects. , 1990, The American journal of medicine.
[5] H. Starnes,et al. Preliminary report: effects of interleukin-1 on platelet counts , 1990, The Lancet.
[6] B. Haynes,et al. Immature human thymocytes can be driven to differentiate into nonlymphoid lineages by cytokines from thymic epithelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Moore,et al. Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model. , 1989, Blood.
[8] A. Karim. The pharmacokinetics of Norpace. , 1975, Angiology.